Cargando…
Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies
Polycystic ovary syndrome (PCOS) is marked in 30 to 40% by insulin resistance and hyperandrogenism. Myo-inositol (MI) increases insulin sensitivity, decreases hyperandrogenism and improves the menstrual cycle. Its effect during assisted reproductive technologies (ART) has been studied by many author...
Autores principales: | Merviel, Philippe, James, Pandora, Bouée, Sarah, Le Guillou, Mathilde, Rince, Camille, Nachtergaele, Charlotte, Kerlan, Véronique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816413/ https://www.ncbi.nlm.nih.gov/pubmed/33468143 http://dx.doi.org/10.1186/s12978-021-01073-3 |
Ejemplares similares
-
Myo-Inositol’s Role in Assisted Reproductive Technology: Evidence for Improving the Quality of Oocytes and Embryos in Patients With Polycystic Ovary Syndrome
por: Gupta, Deepti, et al.
Publicado: (2020) -
Comparing the Efficacy of Myo-Inositol Plus α-Lactalbumin vs. Myo-Inositol Alone on Reproductive and Metabolic Disturbances of Polycystic Ovary Syndrome
por: Kamenov, Zdravko, et al.
Publicado: (2023) -
The “Asthma-Polycystic Ovary Overlap Syndrome” and the Therapeutic Role of Myo-Inositol
por: Guarnieri, Gabriella, et al.
Publicado: (2023) -
Management of polycystic ovary syndrome among Indian women using myo‐inositol and D-chiro-inositol
por: Vyas, Lila, et al.
Publicado: (2022) -
Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes
por: DiNicolantonio, James J, et al.
Publicado: (2022)